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HIV Evolution: Drug Targets and Resistance
Student Activity
Background
Once the human immunodeficiency virus (HIV) binds to a
host immune cell through the interactions of the envelope
protein with CD4 and a coreceptor, the host and virus
membranes fuse and the HIV core, called the matrix/capsid,
containing its RNA genome and related proteins enter the
cell. The matrix/capsid core breaks down and releases
HIV's two single-stranded RNA genome molecules into the
cell's cytoplasm. Reverse transcriptase then synthesizes a
DNA copy of HIV's RNA genome. The double-stranded
DNA copy is then transported to the nucleus where it is
integrated into the host's genome by the enzyme integrase.
This integrated copy is called a provirus. Once these
provirus copies are integrated, there is no way to remove
them from the host's genome.
Using the host cell's protein machinery, including
ribosomes and other proteins involved in the translation
process, the provirus is transcribed into RNA molecules
and translated into HIV proteins. Once synthesized, the
HIV components assemble near the cell membrane. During
this process, the immature polypeptide chains are cleaved
and processed by protease, another HIV enzyme, resulting
in mature, functional HIV proteins. Millions of new virus
particles, each potentially capable of infecting other cells,
can be produced from one infected CD4-positive cell.
Scientists are trying to develop drugs that can interfere with
each step in the HIV lifecycle to stop the release of new
viral progeny.
A potential target for antiretroviral drugs is the HIV
protein, protease. When HIV progeny are released, they are
‘immature’ and noninfectious until protease cleaves certain
proteins ‘maturing’ the virion. The structure of the protease
enzyme is a homodimer, composed of two identical protein
subunits that come together to form an active site (see Fig. 1).
Each protein chain subunit is 99 amino acids long. Once
folded properly, amino acid residues in the active site of the
enzyme include the Asp–Thr–Gly sequence at positions 25
to 27, which are important for its enzymatic action, and
Val82 and Ile84, which are accessible in the active site. If
protease activity is blocked, ‘new’ viruses remain immature
(Boden and Markowitz 1998; Resch et al. 2005).
Currently, nine protease inhibitors are available to treat
HIV-infected individuals (http://www.aidsmeds.com). Rito-
navir is one of these inhibitors. Research has shown that
amino acid residues Val82 and Ile84 among others are
important for ritonavir to bind to protease.
For another example, the first antiretroviral drug devel-
oped for HIV, AZT, is a chemical compound similar in
structure to DNA nucleotides. AZT blocks the action of the
reverse transcriptase enzyme. Early testing of AZT in
patients resulted in decreased viral loads and decreased
HIV replication. However, this inhibition lasted only a short
time as HIV evolved so that reverse transcriptase could
function even in the presence of the inhibitor. HIV can
evolve resistance to any monotherapy currently in use. The
appearance of these drug-resistant strains are a growing
concern for researchers and HIV-infected patients, as these
strains can be passed on to others, making the fight against
HIV even more difficult (HIV Drug Resistance Database,
http://hivdb.stanford.edu). Today, numerous antiretroviral
Evo Edu Outreach (2008) 1:184–188
DOI 10.1007/s12052-007-0024-5
B. Rybarczyk (*)
University of North Carolina at Chapel Hill,
Chapel Hill, NC 27599, USA
e-mail: brybar@unc.edu
drugs have been developed and approved for use by HIV-
infected individuals. These drugs are often taken as a
cocktail, different types of inhibitors taken at the same time.
A typical cocktail or drug combination will include at least
one reverse transcriptase inhibitor and a protease inhibitor.
Recently, integrase inhibitors have been developed and are
in clinical trials; however, no compound in this class has
been approved for therapy.
Preactivity Questions
1. If a polypeptide contains 99 amino acids, how many
nucleotides does this represent?
2. Briefly describe the steps of how HIV evolution might
occur in the presence of antiretroviral drugs.
3. Where in the host genome would it be most advanta-
geous to insert a copy of the HIV genome? Where
would it be most disadvantageous?
4. In terms of HIV evolution, why is it more effective to
take multiple HIV drugs as opposed to only taking one
drug?
Protease Sequence Analysis Activity
Case
John, an HIV positive individual, was given ritonavir
monotherapy over a period of 1.5 years. Blood samples were
taken at regular intervals to monitor his virus load, CD4 cell
count, and for genotype analysis. John began to experience
some minor side effects from the drug treatment last week.
Hypotheses
Generate several testable hypotheses to predict the evolu-
tionary pattern of amino acid changes in HIV protease over
time in this patient.
Data
Viral RNA was isolated from the blood samples; the HIV
protease gene was amplified by PCR and sequenced. Each
sequence is given a unique name and can be found in the
file “protease sequences.txt”.
Sequence Analysis
Quick guide for Biology Workbench
(http://workbench.sdsc.edu/)
1. Log into Biology Workbench, click the “Session
Tools” button, select New, give your session a name,
click Start New Session.
2. Upload sequences into the session. Batch uploading as
described below will upload all the sequences from the
one file provided and then separate each sequence so
you can choose specific ones to work with.
& Click the Protein Tools button since the data are
amino acid sequences.
& Click Add button. Browse your desktop to upload the
sequence file “protease sequences.txt” into your
session. Click the Upload File button, then click the
Save button at the bottom of your sequence text boxes.
3. Now each sequence is uploaded separately into your session
and you are ready to do more advanced manipulations.
4. Alignments:
& Select the sequences you want to align by clicking
the box next to each sequence name.
& Select appropriate alignment algorithm (CLUSTALW
—Multiple Sequence Alignment, will suffice for this
exercise).
& The next window will allow you to change various
parameters. No need to change anything for this
analysis so click the Submit button. Your sequences
will be aligned.
& You can save screen shots of your alignments (Print
Screen button on the PC) and paste into a blank
document for further analysis or just highlight the text
and copy and paste into a document. Make sure you
include the reference sequence named “ref_NL43” in
each of your alignments as the comparison sequence.
Analysis Questions
1. What are your observations and conclusions from the
sequence alignment data? Why would some amino
acids be conserved and others change over time? Does
the data support or refute your propose hypotheses?
Fig. 1 Structure of HIV protease: The 3-D structure shows protease
as a homodimer. The black outline box indicates the enzyme's active
site. Imagine that a long polypeptide chain is perpendicular to this flat
surface going through the open active site of the enzyme
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2. What are the advantages and disadvantages of
inhibiting protease function? Why would inhibiting
integrase be considered a more effective approach
to block HIV replication?
3. If you are a researcher investigating HIV, propose
two additional molecular approaches to inhibit HIV
replication and infection.
HIV Evolution Drug Targets and Resistance
Instructor Guide
Introduction
Currently, there are nearly 40 million people worldwide
affected by HIV/AIDS (UNAIDS/WHO, www.unaids.org).
The human immunodeficiency virus (HIV) has become a
major health epidemic. Although basic scientific research
has uncovered many facets of the biology of the virus,
many questions remain unanswered. Although research has
lead to many treatment options in the form of antiretroviral
drugs, there is currently no cure for HIV infection.
HIV uses three main enzymes during its life cycle. Reverse
transcriptase converts HIV's RNA genome into DNA, integrase
integrates multiple copies of the HIV genome into the host
genome, and protease cleaves immature polypeptide chains
into shorter chains for proper folding into mature proteins.
This module begins to address a common misconception
that during antiretroviral treatment, the host, in this case a
human, evolves immunity against the drugs that become
ineffective. It is not the host that evolves but rather it is the
virus itself that can alter its molecular composition to evade
the effects of the drugs making them ineffective.
Learning Objectives
& Describe the process of microevolution of the protease
enzyme.
& Propose possible selective pressures involved in virus
evolution.
& Analyze molecular evidence for the evolution of the
HIV protease enzyme.
& Propose approaches to more effectively treat HIV
infection with antiretroviral drugs.
Implementation
& This lesson is primarily targeted to undergraduate
students who have previous knowledge of basic cell
biology and genetics.
& Students should have basic knowledge of the HIV lifecycle
and the immune system. Students and instructors should
visit the Centers for Disease Control and Prevention
website (http://www.cdc.gov/hiv) and consult other re-
sources for background information about HIV infection.
& Students can answer the preactivity questions using
reliable internet resources and cite the references they
used. Answers can be shared at the start of the sequence
analysis activity (5 min).
& A computer with internet connectivity is needed for
each pair of students to perform the sequence analysis
activity outlined below. As an alternative, instructors
can provide students the sequence alignment in the
Answer Key below and then ask students to analyze this
data to answer the questions.
& Students will use actual amino acid sequences to
determine specific changes that occur during the course
of infection as evidence of microevolution.
& Any program that has sequence alignment tools and
uses sequences in FASTA format will be sufficient.
One suggested resource is Biology Workbench (http://
workbench.sdsc.edu/), a free, student-friendly bioin-
formatics resource.
& Once students are logged in, they will need to upload the
protein sequence data file “protease sequences.txt” pro-
vided in this module. The sequences can be uploaded in
batch. Students will use the CLUSTALW—Multiple
Sequence Alignment function to compare sequences.
& A reference sequence is provided in the data named
“ref_NL43”
& Sequence alignment and data collection can be performed
in a 50-min period followed by a 30-min debriefing
session to discuss the results and “Analysis Questions”.
Answer Key
Preactivity questions:
1. If a polypeptide contains 99 amino acids, how
many nucleotides does this represent?
1 amino acid represents 3 nucleotides, thus 99 amino
acids=297 nucleotides.
2. Briefly describe the steps of how HIV evolution
might occur in the presence of antiretroviral drugs.
Random mutations occur in the RNA genome when
reverse transcriptase converts the RNA into DNA,
these mutations are not corrected and are passed on in
subsequent replication cycles. Selective pressures will
change the frequency of certain variants in a popula-
tion. Those virions adapted to a specific environment
are considered “fit” and will survive. In this case, the
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selective pressures are the antiretroviral drugs used to
treat HIV infection.
3. Where would it be most advantageous to insert a
copy of the HIV genome into the host genome?
Where would it be most disadvantageous?
It would be most advantageous to insert a provirus into
areas where there is a high rate of transcription (e.g.,
near ribosomal genes), where lots of genes are
transcribed all the time. This will ensure that the
HIV genome is copied when the host genome is
copied. Other advantageous areas would be near active
promoter regions. Areas of insertion that would be
disadvantageous include areas where essential genes
are located. Disrupting a host's essential genes which
are necessary for survival would decrease HIV's
chances of replicating and being passed on.
4. In terms of HIVevolution, why is it more effective to
take multiple HIV drugs as opposed to only taking
one drug?
As demonstrated with AZT monotherapy, HIV posi-
tive individuals can develop drug resistance more
quickly as compared to those individuals taking many
types of antiretroviral drugs simultaneously. Multiple
drugs targeting reverse transcriptase and protease
make it more difficult for HIV to develop resistance.
Of course, the disadvantage would be that multidrug-
resistant strains of HIV develop over time.
Suggested hypotheses:
Students should propose ideas related to the develop-
ment of mutation in protease over time that would decrease
the affinity of the protease inhibitor yet still ensuring the
enzyme works. Thus the active amino acids between 25 and
27 would be conserved over time, but other amino acids
involved in binding ritonavir would change over time.
Analysis questions:
Sample alignment:
1. What are your observations and conclusions from
the sequence alignment data? Why would some
amino acids be conserved and others change over
time? Do the data support or refute your propose
hypotheses?
Thinking back to the important amino acids in the
active site, positions 25–27 (Asp–Thr–Gly) are
conserved throughout the entire sampling time.
These positions are conserved, as these are the
important amino acids involved in the enzyme's
function as an aspartyl protease. However, amino
acid 82 does change over time suggesting that this
amino acid is involved in the binding of the inhibitor,
ritonavir. Thus position 82 changes over time,
providing evidence of drug resistance. By day 399,
ritonavir may not bind to protease as efficiently
because of changes at position 82 (and probably
position 54 and 71), but the enzyme is still active
because of the conservation of amino acids 25–27.
2. What are the advantages and disadvantages of
inhibiting protease function? Why would inhibiting
integrase be considered a more effective approach
to block HIV replication?
The advantages would be that inhibiting protease
blocks the cycle of HIV replication. Developing
specific inhibitors just for HIV protease would
directly target this enzyme and stop its function
and production of new HIV virions. This would
decrease the amount of virus in the host. The
disadvantage is that protease is similar to other
human protease enzymes. Thus, taking inhibitors
commonly results in side effects caused by inhibit-
ing other human enzymes needed for normal
functioning. Inhibiting integrase would be consid-
ered more effective, as it would prevent the
integration of HIV into the host's genome. Prevent-
ing integrase activity would lead to a decrease in
chronic HIV infections.
  10   20     30    40       50         60
ref_NL43             PQITLWQRPL VTIKIGGQLK EALLDTGADD TVLEEMNLPG RWKPKMIGGI GGFIKVRQYD
patientA_day1        ---------- ---------- ---------- -----—S--- ---------- ----------
patientA_day175      ---------- ---------- ---------- ------S--- ---------- ---V------
patientA_day399      ---------- ---------- ---------- --FQ-—S--- ---------- ---V------
                         
       70       80    90  
ref_NL43             QILIEICGHK AIGTVLVGPT PVNIIGRNLL TQIGCTLNF 
patientA_day1        -VP------- ------I--- ---------- --L------ 
patientA_day175      --P------- ------I--- -T-------- --L-----S 
patientA_day399      --P------- V-----I--- -A-------M –-L------ 
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3. If you are a researcher investigating HIV, propose
two additional molecular approaches to inhibit HIV
replication and infection.
Inhibiting any of the three HIV enzymes would be
key targets. Inhibiting the binding of HIV to the
host immune cell is also another approach. These
approaches would block the envelope protein
(gp120), CD4, and the two coreceptors, CCR5 and
CXCR4. Other approaches would include prevention
via a vaccine. Vaccines based on gp120 and other
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